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Abstract
Water-soluble polymers are promising drug carrier materials. Especially polysaccharide
graft copolymers are desirable for this purpose as they combine the favorable features of
biopolymers, such as biocompatibility and biodegradability, with the controlled structure
and functionality of synthetic polymers. This thesis examines water-soluble hyaluronic
acid (HA) graft copolymers with cleavable arms as potential vehicles for sustained
intravitreal drug delivery.
Retinal diseases are the leading cause of visual impairment in the aging Western
societies, but drug delivery to the back of the eye is complicated by multiple barriers.
Intravitreal injections so far yield the highest bioavailability of drugs, however they need
to be repeated frequently due to the rapid clearance of the therapeutics. Sustained delivery
of drugs over extended periods of time is a promising strategy to prolong the injection
intervals. Macromolecular drug delivery vehicles can help to reduce the clearance rate due
to their high molecular weight and low diffusivity.
The studied graft copolymers are based on a high molecular weight HA backbone and
poly(glyceryl glycerol) (PGG) side chains attached via hydrolysable linkers. HA is a
natural constituent of the vitreous and used to prolong the vehicle’s retention time in the
eye. PGG is a multihydroxyfunctional polyether featuring a poly(ethylene glycol) (PEG)
backbone and pendant 1,2-diol moieties in every repeating unit. As such, PGG possesses
similar biocompatibility and antifouling properties as PEG, while being amenable to the
conjugation of multiple drugs, probes and targeting moieties.
HA was functionalized with hydrolysable alkynyl linkers for use in click grafting. The
effect of modifications (i.e. amidation, esterification and click reaction) on HA properties
was studied and the reaction conditions were optimized to minimize degradation while
achieving efficient derivatization. Azido-functional PGG was prepared by ring-opening
polymerization of epoxide monomers. Functionalization of PGG hydroxyl groups was
explored to establish strategies for conjugation of drugs, probes and targeting molecules.
For example, PGG could be efficiently labeled with rhodamine B boronic acid, due to
formation of reversible boronic esters with the pendant 1,2-diol moieties.  HA-PGG graft
copolymers were prepared by copper-mediated azide-alkyne cycloaddition (CuAAC).
The synthesized materials were studied under simulated physiological conditions to
determine their stability and the cleavage of hydrolysable bonds. The HA backbone was
stable during one month of incubation in buffer or vitreous liquid. The polymer-from-
polymer release of PGG grafts from the HA-PGG ester copolymer was investigated and
the hydrolysis rates were quantified. Hydrolytic cleavage of PGG chains from HA was
significantly slower than cleavage of the small molecular weight alkynyl linkers, and was
attributed to steric crowding at the ester bond. Hence, graft copolymers with cleavable
arms have the potential to achieve longer lasting release than polymeric prodrugs with
drugs attached directly to the backbone.
The biocompatibility of PGG and HA-PGG copolymers was tested in cell cultures.
The materials exhibited similar levels of cell viability as polyvinyl alcohol, which is FDA-
approved for ocular applications.
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1 Introduction
1.1 Water-soluble polymers as drug carriers
Water-soluble polymers have long been recognized for their potential as drug carriers.1–3
In 1975, Helmut Ringsdorf described the ideal structure of such a carrier.4 It consists of a
water-soluble, non-toxic polymer backbone with drugs attached via degradable spacers
that facilitate their release under predefined conditions and targeting moieties that induce
specific interactions at the disease site (Figure 1a). Compared with small drugs, these
polymer-drug conjugates exhibit significantly different pharmacokinetic and pharmaco-
dynamic properties (Figure 1b).5 The most important properties are improved solubility
and retarded excretion from the body, which is affected by the high molecular weight.4
Figure 1 a) Schematic of an ideal water-soluble polymeric drug carrier redrawn from
reference 6. b) Effects of the structure of polymer-drug conjugates on the phases of
drug action.4
Both synthetic and natural polymers have been used as drug carriers. They include
poly(ethylene glycol) (PEG), poly(N-(2-hydroxypropyl) methacrylamide (PHPMA),
polyamidoamine (PAMAM), dextran, chitosan and carboxymethylcellulose.7,8 While
synthetic polymers, such as PHPMA, are easy to prepare and modify, their usable
molecular weight range is limited. Non-degradable polymers of sizes larger than the renal
threshold (~5∙104 g mol-1) accumulate in the body.9 Biopolymers, such as polysaccharides,
are naturally high in molecular weight (up to 107 g mol-1) and besides are biocompatible
and biodegradable.10 On the other hand, polysaccharides are often difficult to modify and
have a limited number of drug attachment sites, if their structural and functional integrity
is to be preserved.11
A combination of synthetic and natural polymers, as in polysaccharide graft
copolymers, overcomes the limitations of the individual components to achieve very high
molecular weight and degradability into smaller fragments suitable for renal clearance.
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Furthermore, grafting of polysaccharides with synthetic polymers is a way to introduce
diverse functionalities while maintaining the bioactive properties of the polysaccharide by
a low grafting density.
1.1.1 Polysaccharide graft copolymers
Polysaccharide graft copolymers are prepared by either grafting of ready-made synthetic
polymers onto a polysaccharide backbone12–14 or by polymerization from the
polysaccharide11,15,16 (Figure 2). With the grafting onto approach, both backbone and side
chain polymers can be tailor-made and characterized prior to coupling, but the grafting
density is typically limited due to steric hindrance.17 With  grafting from, high grafting
densities and narrow molecular weight distributions are achieved, but the side chain
lengths are less controlled.11 Both  methods  lead  to  copolymers  that  can  display  new
functional properties,18 improved solubility,19 or response to environmental changes.20 For
example, cationic polysaccharide graft copolymers with positively charged chitosan
backbone or cationic poly(2-(dimethylamino)ethyl methacrylate) (PDMAEMA) side
chains are investigated for gene delivery applications, because of their ability to complex
negatively charged DNA fragments.21,22 Thermoresponsive graft copolymers of dextran,
chitosan or carboxymethylcellulose with poly(N-isopropylacrylamide) (PNIPAM) are
used to encapsulate drugs,23,24 while hyaluronic acid-g-PNIPAM is widely studied as
injectable hydrogel scaffold for tissue engineering.25–27
Figure 2 Synthesis of polysaccharide graft copolymers. FRP - free radical polymerization,
ROP - ring-opening polymerization, ATRP - atom-transfer radical polymerization,
RAFT - reversible addition-fragmentation chain-transfer polymerization, ROMP -
ring-opening metathesis polymerization.
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In the present thesis, water-soluble, high molecular weight polysaccharide graft
copolymers with cleavable arms are introduced as drug delivery vehicles for the treatment
of eye diseases. These vehicles are designed to undergo a two-stage release specifically
tailored to the requirements of back of the eye drug delivery (Figure 3). First, synthetic
multifunctional polymer grafts, carrying drugs and targeting ligands, are released from the
polysaccharide backbone upon exposure to a first trigger. Second, release of drugs from
the grafts takes place after target-mediated cell uptake, which initiates a second trigger.
The release mechanism relies on carefully coordinated chemical linkages between
copolymer backbone and side chains, as well as between side chains and drugs. While the
drug-conjugation has to remain intact in the extracellular environment inside the eye, the
linkages between side chains and backbone need to be slowly cleaved.
Figure 3 Two-stage release from polysaccharide graft copolymers: 1) Sustained release of
drug- and targeting moiety-carrying grafts upon exposure to first trigger. 2) Release
of drugs from the grafts at the site of action initiated by the second trigger.
1.1.2 Hydrolytically cleavable bonds
Different chemical bonds are used to attach drugs and ligands to polymers and they have
varying stabilities in physiological conditions. Bonds can be cleaved by either enzymatic
or non-enzymatic hydrolysis.28 The hydrolytic stability at neutral pH increases from esters
< carbonates < carbamates (urethanes) < hydrazones < amides (Scheme 1).28 Furthermore,
hydrazones and acetals are rather stable at neutral pH, but undergo hydrolysis under
mildly acidic conditions (i.e. pH 5.0) after uptake into the endosomes and lysosomes of
cells.29,30 Peptide linkers are stable in serum, but are readily cleaved by intracellular
enzymes, and disulfide linkages are reduced by glutathione over-expressed in tumor
cells.31 The rate of hydrolysis of polymer-drug conjugates is influenced by the type of
bonds, hydrophilicity of neighboring groups and steric crowding at the reaction center.
Hydrophobic neighboring groups slow down the hydrolysis rate.32,33 In contrast, use of a
spacer between the drug and the polymer backbone decreases the steric hindrance and thus
increases the release rate significantly.34
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The copolymer in this work is based on hyaluronic acid (HA), a naturally occurring
polysaccharide and constituent of the vitreous, and multihydroxyfunctional poly(glyceryl
glycerol) (PGG) side chains. Release of PGG grafts has to occur in the neutral aqueous
environment of the vitreous body, i.e. the clear gel inside the eye filling the space between
lens and retina. This can be achieved by non-enzymatic hydrolysis of ester bonds or by
degradation of the hyaluronic acid backbone in presence of hyaluronan-digesting enzymes
(hyaluronidases).35 Hence linkers between HA and the grafts can be ester-based or non-
degradable, e.g. amides. The attachment of drugs to the polymer grafts can be realized
through hydrazone bonds, which are stable at neutral pH and readily cleaved after cell
uptake. Targeting ligands and probes will be irreversibly linked to the grafts using amide
and thiourea bonds.
1.2 Drug delivery to the back of the eye
1.2.1 Posterior segment ocular diseases
Posterior segment ocular diseases are the leading cause of visual impairment and blindness
in the Western societies and their prevalence is expected to increase in future with the
proportion of elderly people.36–38 Diseases, such as age-related macular degeneration
(AMD), diabetic retinopathy and macular edema, affect the tissues of the retina and
choroid (Figure 5). They are caused by extensive neovascularization and leaky blood
vessels of the choroid, which leads to inflammation and damage in retinal cells.39
Dysfunction of the retinal pigment epithelium (RPE) due to oxidative stress or
inflammation is the primary event that leads to deterioration of vision in AMD.40,41 RPE
cells are essential for proper visual function as they provide nutrients and protection for
the photoreceptors, and serve as the waste disposal system of the retina. Therefore they are
recognized as a target site for the treatment of retinal diseases.42
AMD and diabetic retinopathy often require therapy over several years and can be
managed with anti-angiogenic drugs that inhibit the growth of new blood vessels.
Currently explored therapeutics include corticosteroids (e.g. dexamethasone,
triamcinolone acetonide) and biologics, such as recombinant fusion proteins (aflibercept),
Fab-fragments (ranibizumab) or monoclonal antibodies (bevacizumab) (Figure 4).36,39,43
14
Dexamethasone
392 g mol-1
Triamcinolone acetonide
435 g mol-1
Aflibercept
115 kg mol-1
Bevacizumab
149 kg mol-1
Ranibizumab
48 kg mol-1
a) b)
Figure 4 Structures of corticosteroids (a) and biologic therapeutics (b) used in treatment of
posterior segment ocular diseases.44
1.2.2 Physiology and barriers of the eye
The eye features several barriers that effectively hinder drug transport from topically
applied formulations (e.g. eye drops) and systemic administrations to the vitreous (Figure
5).45 Intravitreal injections yield the highest retinal drug bioavailability, but frequent
injections can increase the probability of complications, such as ocular inflammation,
retinal detachment, hemorrhage or endophthalmitis.46–48 Repeated injections are required
due to the short half-life of drugs in the eye.49
Clearance of drugs from the vitreous takes place via two pathways (Figure 5, blue
arrows). Small molecular weight hydrophobic drugs readily permeate across the blood-
retinal barrier and enter systemic blood circulation via the posterior route. This pathway is
impeded for larger hydrophilic molecules, which have limited permeability in the RPE.50
Furthermore, drugs are eliminated via the anterior route by constant vitreous outflow into
the anterior chamber with a rate of clearance depending on the diffusivity of the drug.51 As
a result of their low diffusivity and hindered permeation across the RPE, hydrophilic
macromolecules exhibit extended residence times in the vitreous.52,53
The vitreous humor consists of a highly hydrated network of negatively charged HA
with hydrophobic domains of collagen and a mesh size of about 500 nm.51,54 Hence,
neutral or negatively charged molecules and particles of up to 500 nm have similar
mobility as in water, while positively charged molecules and larger particles aggregate
with the vitreous components.55 Furthermore, access to the retina and RPE is guarded by
inner and external limiting membranes (ILM and ELM) that prevent passage of
macromolecules bigger than 10 nm.50,56 An ideal drug carrier is thus large enough to show
prolonged residence time in the vitreous, but also has a way to penetrate the retinal layers
and reach the RPE.
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Figure 5 Structure of the eye with routes of drug administration (I-III) and clearance (IV-V)
illustrated, redrawn from reference 45 and article III. Selected methods of
administration: I) intravitreal injection, II) topical application, III) drug diffusion
across the blood-retinal barrier after systemic application. Clearance pathways: IV)
drug elimination via posterior route across blood-retinal barrier, V) diffusion of
drugs into anterior chamber and clearance by aqueous humor turnover (anterior
route).
1.2.3 Drug delivery approaches
In recent years many polymeric drug delivery vehicles were proposed to reduce the
frequency of required intravitreal injections and to deliver drugs at controlled levels for
prolonged times. These include micro- and nanoparticles, dendrimers, hydrogels and
polymer implants.43,57–59 Ozurdex® is a biodegradable polymer implant consisting of a
poly(lactide-co-glycolide) matrix loaded with dexamethasone.60,61 Ozurdex® enables
controlled drug delivery over months or years, but its implantation is more invasive than
standard intravitreal injections. Implants have further been shown to increase the
intraocular pressure and the progression of cataract.62 In contrast, drug-loaded polymer
micro- or nanoparticles can be injected. Their distribution in the vitreous greatly depends
on their size and surface charge. Nanoparticles have lower settling velocities in the
vitreous than microparticles, which leads to longer retention times.63 However  the  high
surface to volume ratio often results in burst drug release from the nanoparticles.64 Particle
formulations can lead to visual disturbances and aggregates may activate
macrophages.65,66
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Nanoparticle carriers were modified with different targeting ligands to enhance their
uptake by RPE cells. Recognition was achieved with biologics, such as arginyl-glycyl-
aspartic acid (RGD)-peptides and transferrin,67 cell penetrating peptides,42 or nanoparticles
made of human serum albumin.68 Furthermore, folic acid69,70 and HA56,71 were shown to
induce receptor-mediated endocytosis in RPE cells.
The proposed water-soluble HA-PGG graft copolymer presents a novel approach to
intravitreal drug delivery. The vehicle is designed to minimize visual disturbances by
being dissolved and to provide long retention time in the vitreous through its high
molecular weight. Slow cleavage of grafts from the backbone allows for sustained release
of polymer fragments that are small enough to penetrate into retinal layers, but large
enough to exhibit significant vitreal half-lives. The multifunctional PGG can carry a
variety of drugs, probes and targeting ligands.
1.3 Hyaluronic acid
HA is a linear polysaccharide consisting of disaccharide repeating units of β(1,4)- and
β(1,3)-linked D-glucuronic acid and N-acetyl glucosamine (Scheme 2). It is present in the
extracellular matrix of vertebrates and plays a role in cell proliferation, differentiation and
tissue repair.72 For  this  study  it  was  selected  for  its  high  molecular  weight  and
biocompatibility as a natural constituent of the vitreous. Chemical modification of HA can
be achieved in different ways as summarized by Schanté and colleagues.73 Shortly, the
glucuronic acid is commonly esterified, amidated or oxidized, while the primary hydroxyl
group of N-acetyl glucosamine can be targeted for ether, ester, or carbamate formation.
The reducing end of the polysaccharide is often used in reductive amination to yield block
copolymers.74
Scheme 2 Chemical structure of sodium hyaluronate.
1.3.1 HA (bio)degradation
Chemical modification of HA is subject to two major limitations. The first problem is the
pronounced degradation of the polymer under harsh reaction conditions. To preserve the
high  molar  mass  of  HA,  strongly  alkaline,  acidic  or  oxidative  solutions,  heat,  shear  and
microwave irradiation should be avoided.75,76 The  second  constraint  is  the  solubility  of
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sodium hyaluronate (the prevalent form of HA), which is limited to aqueous solutions.
Under these conditions, many of the aforementioned reactions proceed with low efficiency
and require excess of reagents. Hence, these reactions are unsuitable for direct grafting of
HA with elaborately prepared drug- and ligand-carrying polymeric side chains. Exchange
of the sodium counter ion for tetraalkylammonium ions or acidification of HA helps to
solubilize the polymer in dimethyl sulfoxide (DMSO),77,78 but these treatments lead to
further degradation and complicate the purification of the products.79,80 Small and reactive
linkers, introduced under mild aqueous reaction conditions, can facilitate the grafting of
polymer side chains.
Another aspect of HA modification is its impact on the biodegradation behavior.
Masking of the D-glucuronic acid moieties of HA inhibits its recognition by hyaluronidase
and slows down its degradation in the body.81,82 Hyaluronidase is present in the human
vitreous,35 therefore functionalization of the D-glucuronic acids possibly prolongs the
already  long  residence  time  of  HA  in  the  eye  (half-life  of  500  kg  mol-1 HA in rabbit
vitreous is 30 days).83
1.3.2 Introduction of reactive linkers onto HA
As mentioned above, polysaccharide graft copolymers with cleavable arms may comprise
hydrolytically labile ester or stable amide bonds between the backbone and side chains,
depending on the mode of cleavage (i.e. hydrolysis of the linker or enzymatic degradation
of the backbone). In addition, the linkers must be accessible for efficient coupling of
polymers, resulting in the choice of clickable linkers. Click chemistry, a term coined by
Sharpless and colleagues in 2001,84 refers to reactions that are chemoselective, high
yielding, and devoid of offensive byproducts. They include the widely used copper-
mediated azide-alkyne cycloaddition (CuAAC or just click reaction), strain-promoted
azide-alkyne cycloaddition, Diels-Alder cycloaddition, thiol-ene conjugation, and recently
triazolinedione-based reactions with (di)enes.85
Amidation of HA with clickable linkers is commonly achieved by carbodiimide-
mediated coupling.86–88 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) is a
water-soluble coupling agent used to activate carboxyl groups by formation of an
O-acylisourea intermediate (Scheme 3).89 The intermediate is highly unstable in aqueous
solution and rearranges into an unreactive N-acyl urea byproduct, which is covalently
bound  to  HA.  Addition  of N-hydroxysuccinimide (NHS) or 1-hydroxybenzotriazole
(HOBt) can stabilize the amine-reactive intermediate by converting it into an active
ester.90 However the method typically produces low degrees of substitution (DS) and
requires accurate control of pH (reactivity of EDC is highest at acidic pH, while amines
are reactive at neutral or alkaline pH), which is most inconvenient. Triazine-based
coupling agents, such as 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium
chloride (DMT-MM), yield higher DS than EDC/NHS, while demanding no specific pH
control and using reduced quantities of coupling agent.91,92
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Scheme 3 Carbodiimide-mediated amidation of HA. Reactive O-acylisourea intermediate
rearranges in water to N-acyl urea byproduct or reacts with amine to form the
desired amide (competing reactions). The intermediate can be stabilized with NHS or
HOBt as active ester, retaining its amine-reactivity.
Table 1 Literature procedures for esterification of the HA glucuronic acid groups.
# HAa Activatorb Reagent Solventc DS / % Ref.
1 Na salt TEA Glycidyl methacrylate PBS / DMF
(1:0 to 1:1 v/v)
14-90 93
2 Na salt DCC / DMAP Curcumin H2O / DMSO
(1:1 v/v)
1.4 94
3 Free acid Diazomethane Trimethylsilyl diazomethane DMSO 80-100 95
4 Free acid DCC / DMAP Paclitaxel DMSO 5 78
5 TBA salt Alkyl halide Dodecyl / Octadecyl bromide DMSO 1-5 96
6 TBA salt Tosylate or
alkyl halide
Tetraethylene glycol
ditosylate / dodecyl bromide
DMSO 0.5-4.7 77
7 TBA salt Alkyl halide Alkyl iodide (n = 1-6) DMSO 50-100 97
aForm of hyaluronic acid employed in reactions (TBA - tetrabutylammonium). bDCC - N,N’-
dicyclohexylcarbodiimide, DMAP - 4-dimethylaminopyridine, TEA - triethylamine. cDMF  -
dimethylformamide, PBS - phosphate-buffered saline.
Esterification of the glucuronic acid groups of HA is usually accomplished in two
steps. First the polysaccharide is converted into its acidic form or quaternary ammonium
salt; then it is dissolved in an aprotic solvent and reacted with an esterifying agent (Table
1). HA derivatives with high DS are often insoluble in water.10 Ethyl and benzyl esters of
HA, termed HYAFF® 7 and HYAFF® 11, are widely studied as membranes, fibers,
sponges, and microspheres for biomedical applications.98 A few studies report the
esterification of sodium hyaluronate in aqueous solvent mixtures (Table 1, entries 1&2),
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but yield very low DS or use tremendous excess of reagents (i.e. 50-100-fold molar excess
of glycidyl methacrylate compared to carboxyls). To minimize the degradation of the
polysaccharide backbone, esterification of untreated HA with clickable linkers is one topic
of this work.
1.3.3 HA in ophthalmology
HA has been employed in ophthalmic viscosurgery since the early 1980s.99 Used  in  the
form of highly viscoelastic solutions, it serves as vitreous replacement after vitreoretinal
surgery, for tissue protection during corneal transplantation or as topical formulation to
hydrate the surface of the eye. Lai et al. reported cross-linked HA hydrogel discs as cell
sheet delivery systems for corneal epithelial cells.100 After implantation of the discs into
the anterior chamber of rabbit eyes, they noticed a marked difference in biocompatibility
between glutaraldehyde- and EDC-cross-linked gels. The latter were tolerated much
better, provoking no inflammation, and demonstrating the influence of coupling agent on
the biocompatibility. Furthermore, UV-curable hydrogels, consisting of thiol-modified HA
and alkene-modified PAMAM dendrimers, were investigated as drug delivery systems for
the treatment of corneal inflammation.101 Injected between the conjunctiva and sclera, the
gels contained free dexamethasone-carrying dendrimers that were slowly released from
the depot and able to target activated corneal macrophages.
For posterior segment diseases, HA is used as a coating material for different types of
nanocarriers. Gan et al. first demonstrated the targeting ability of HA toward RPE cells.56
They prepared core-shell nanoparticles made of chitosan and coated with 1,2-dioleoyl-sn-
glycero-3-phosphoethanolamine (DOPE) lipids. They covalently attached HA to the amine
groups of DOPE. In cell uptake studies they found that particles of 200-300 nm size were
unable to penetrate the retinal layers of normal rat eyes. The particles only entered the
retina of animals with experimentally induced uveitis, a form of ocular inflammation. In
this case, HA-coated particles showed enhanced uptake by RPE cells due to their
interaction with expressed CD44-receptors. This study illustrates the importance of the
size of potential drug carriers, which need to pass the barriers of the inner and external
limiting membranes to reach their target site. Martens et al. functionalized gene carriers
with HA to improve their mobility in the vitreous and enhance their transfection efficiency
in RPE cells compared to poly(ethylene glycol) coated vectors.71 They further found that
lipoplexes with a covalently bound HA-shell exhibit 8-fold increased transgene expression
compared with uncoated lipoplexes or lipoplexes with electrostatically-bound HA.102
A soluble ocular drug delivery vehicle based on HA is yet unprecedented. Due to the
high molecular weight of the proposed HA-PGG graft copolymer, the targeting ability of
HA will be secondary. The copolymer will be unable to penetrate into the retinal layers as
such,  considering  the  radius  of  gyration  of  a  ~900  kg  mol-1 HA is approximately 100
nm.10,103 Rather, smaller fragments, which are released by hydrolytic cleavage of the side
chains or degradation of the HA backbone, will facilitate the site specific drug delivery to
the RPE. Hence, it is important for the grafts to be multifunctional and display additional
targeting ligands to interact with RPE after they are cleaved from HA.
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1.4 Multifunctional linear polyethers
Poly(ethylene glycol) (PEG) is the most frequently used water-soluble polymer in
biomedical applications. It is attached to proteins, drugs, liposomes, and polymer particles
(PEGylation) to enhance their solubility and circulation time in vivo. The so-called stealth
effect is attributed to PEG's highly hydrated and flexible structure, which shields the
conjugates from protein adsorption, thereby preventing recognition by the immune
system.104 PEG-drug conjugates exhibit intrinsically low payloads, because the linear
polyether has only two functional groups for derivatization.105 Furthermore, formation of
anti-PEG antibodies was observed, causing hypersensitivity and enhanced blood clearance
after repeated injections.106 The concerns about the safety of PEG and its low functionality
have thus led to the search of other hydrophilic polymers as substitutes.107
In recent years, linear polyglycerols (PGs) have emerged as multifunctional PEG
alternatives.108,109 PG features a PEG backbone with pendant hydroxyl groups in every
repeating unit that can be conjugated with a variety of drugs, probes and targeting ligands
(Scheme 4). Poly(glyceryl glycerol) (PGG), which is in the focus of this study, is a linear
PG with pendant glycerol moieties, offering additional options for functionalization while
maintaining a compact size. PGs are highly hydrophilic, possess excellent antifouling
properties and superior biocompatibility compared with PEG, as they are showing neither
activation of the complement system nor red blood cell aggregation or hemolysis.110–112
Linear polyglycerols are prepared by oxyanionic ring-opening polymerization (ROP) of
protected glycidol derivatives (glycidyl ethers).
Scheme 4 Structures of poly(ethylene glycol), polyglycerol and poly(glyceryl glycerol); the
latter is in the focus of this study.
1.4.1 Ring-opening polymerization of epoxides
Epoxide monomers can be polymerized by anionic or cationic ring-opening
polymerization  (AROP  and  CROP),  but  AROP  is  more  efficient  in  achieving  well
controlled molecular weight, dispersity and end group functionality.113 Any pendant
hydroxyl groups of the monomers must be protected during polymerization, otherwise
hyperbranched polyethers are obtained. Acetal protecting groups are commonly used and
afterwards removed under acidic conditions. The polymerization mechanism (Scheme 5)
involves the bimolecular nucleophilic substitution of an initiator on the epoxide ring,
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leading to an alkoxide growing chain, which attacks another monomer. The reaction is
terminated by proton transfer from an acidic compound (often water or alcohols), resulting
in a hydroxyl end group.
Scheme 5 Mechanism of anionic ring-opening polymerization of epoxide monomers initiated
by alkali metal alkoxides (initiation, propagation, termination).113 In case of mono-
substituted epoxides, transfer reactions occur in presence of strongly basic
alkali metal alkoxides.
Alkali metal alkoxides were used to initiate AROP of ethylene oxide and several
glycidyl ether monomers,114,115 but they are strongly basic and abstract protons from
mono-substituted epoxides leading to transfer reactions (Scheme 5). Transfer reactions
strongly limit the molecular weight that can be obtained for polyethers and are more
pronounced at higher temperatures.116 Polymerization temperatures can be effectively
reduced with the help of larger counter ions. For example, use of cesium instead of sodium
or complexation of the counter ion with crown ethers results in decreased aggregation with
the chain end and thus higher reactivity. In this way, side reactions can be suppressed.
Another approach to increase the polymerization rate was developed by Carlotti,
Deffieux et al. using Lewis acidic trialkylaluminum as a monomer activator.117,118 The
aluminum compound forms a complex with the epoxide oxygen, thereby enhancing the
reactivity of the ring α-carbon toward nucleophilic attack. For monomer activation, an
excess of the Lewis acid compared to the initiator is required, as both form a 1:1 complex
together.  A  further  development  was  the  substitution  of  alkali  metal  alkoxides  with
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ammonium salt initiators leading to higher molecular weights and even faster
polymerization kinetics.119 In these systems transfer reactions are greatly suppressed due
to the decrease in chain end basicity by coordination to aluminum.
1.4.2 Post-polymerization modification of poly(glyceryl glycerol)
Heterofunctional polyglycerols, i.e. polymers with different head-, end- and side-groups,
can be obtained in various ways. Use of functional initiators that tolerate the harsh
polymerization conditions leads to α-functional polyethers. For example, protected amine
and thiol head groups, as well as catechol, adamantyl, and cholesterol groups have been
introduced.109 Deffieux’s monomer-activated polymerization method allows for the direct
preparation of α-bromo- and α-azido-polyethers; the latter are useful in click reactions.120
End group modification can be achieved by capping of the “living” chain end with alkyl
halides and anhydrides or functionalization of the protected polymers’ ω-hydroxyl group
by esterification or ether synthesis. This approach was used in the synthesis of propargyl-
terminated PGs and for preparation of methacrylate- and styrene-capped polyglycerol
macromonomers for radical polymerization.121,122
Chemical modification of the pendant hydroxyl groups in deprotected polyglycerol has
been achieved by esterification in dimethylformamide (DMF) with e.g. acetic
anhydride,123 palmitoyl chloride,124 and 3,3-dithiopropionic acid.125 Li and Chau published
a comprehensive study detailing the synthesis of 18 monofunctional and 9
heterobifunctional derivatives of poly(glycerol-co-ethylene oxide) random copolymers,
performing most of the reactions in either tetrahydrofuran or dichloromethane.126 The
authors noted that copolymers with monomer ratios of ethylene oxide/glycidol < 19:1
were insoluble in nonpolar solvents. The limited solubility of PG, and especially PGG, in
common organic solvents is a major drawback compared with PEG. Hence, it is subject of
the present work to develop strategies for efficient conjugation of PGG with functional
moieties, such as drugs, probes and targeting ligands.
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2 Objectives of the study
This study was aimed at synthesizing a water-soluble and biocompatible hyaluronic acid-
based graft copolymer with cleavable arms as a vehicle for intravitreal drug delivery. The
copolymer should exhibit high molecular weight to prolong its retention within the
vitreous and be able to slowly release its grafted side chains. The side chains should be
multifunctional and facilitate the attachment of various bioactive molecules, such as drugs,
targeting ligands and probes.
In this work:
(i) Methods were developed to modify hyaluronic acid (HA) with reactive
groups for efficient grafting of side chains.I,III The influence of reaction
conditions on molecular weight of HA was studied and procedures were
optimized to reduce polysaccharide degradation and to achieve efficient
modification.
(ii) Multifunctional polyether grafts were synthesized by monomer-activated
ring-opening polymerization of epoxides.II Coupling of the pendant hydroxyl
groups with various probes was investigated.II,III Conversion of hydroxyls
into reactive hydrazides for further attachment of drugs and targeting ligands
was accomplished.
(iii) Polyether chains were grafted onto HA-derivatives via copper-mediated
azide-alkyne cycloaddition.III Polymer-from-polymer release of grafts from
the polysaccharide backbone was studied under simulated vitreal
conditions.III Different experimental setups were explored to quantify release
rates. Release kinetics of polymer side chains were compared with release of
small molecules from HA.
(iv) Biocompatibility studies were performed with the synthesized materials in
cell cultures.III
24
3 Experimental
This section briefly describes the synthetic and analytical procedures used in this study.
Detailed instructions can be found from the respective publications.
3.1 Characterization
The structures of all small molecules, polymers and polymer-derivatives were confirmed
by nuclear magnetic resonance spectroscopy (NMR) using a Bruker Avance III 500
spectrometer (1H: 500.13 MHz, 13C: 125.77 MHz). Boronic ester formation between PGG
1,2-diol groups and phenylboronic acid was investigated by diffusion-ordered NMR
(DOSY) using the standard Bruker pulse sequence ledbpgp2s. The  hydrolysis  of  HA-
propargyl ester (c = 1 mg mL-1) to release propargyl alcohol was studied in PBS (pH 7.40)
containing 5 % (v/v) deuterium oxide (D2O)  at  37  °C. 1H NMR spectra were acquired
using a water presaturation pulse (zgpr, pulse strength 1 mW) to partially suppress the
solvent signal.
Molecular weights and distributions of HA(-derivatives) and PGG were determined by
size exclusion chromatography (SEC) in 0.1 M aqueous sodium nitrate (NaNO3) solution
containing 3 % (v/v) acetonitrile. Samples were eluted at 0.8 mL min-1 using a Waters 515
HPLC pump and Waters 2410 refractive index detector. The column set comprised a
TOSOH guard column PWXL and TSKgel columns G3000 PWXL, G5000 PWXL, and
G6000 PWXL. Chromatograms were calibrated with narrow poly(ethylene oxide)
standards (PSS Polymer Standards Service), unless otherwise noted. Protected polyethers
(PIGG) were measured with the same equipment using Waters Styragel guard column and
Styragel HR1, HR2, and HR4 columns. PIGG was eluted with tetrahydrofuran containing
1 % (v/v) toluene and calibrated with narrow polystyrene standards (Scientific Polymer
Products, Inc.).
Fourier transform infrared (FT-IR) spectra were recorded using a Perkin Elmer One
FT-IR spectrometer with attenuated total reflection accessory. Fluorescence measurements
were performed with a Horiba Jobin Yvon FluoroMax-4 spectrofluorometer. Ultraviolet
(UV) spectra were measured using a Shimadzu UV-1601PC UV-visible spectro-
photometer.
3.2 Syntheses
3.2.1 Functionalization of HAI,III
High molecular weight HA (~750 kg mol-1 according to manufacturer) was used in all
syntheses. The products were typically purified by aqueous dialysis and lyophilized.
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Gravimetric yields were generally around 80 %. Degrees of substitution (DS) were
determined by 1H NMR and are given in percent per 100 disaccharide repeating units.
Triazine-mediated amidation of HA was performed according to the procedure of
Bergman et al.91 The coupling agent (DMT-MM) was generated in situ from 2-chloro-4,6-
dimethoxy-1,3,5-triazine (1.0 eq.) and N-methylmorpholine (1.5 eq.) in water/acetonitrile
(3:2 v/v). Functional amines were employed at a 1.5-molar excess compared to the HA
carboxyl groups. NMR kinetic studies were performed in unbuffered D2O with low
molecular weight HA (~1 kg mol-1) and DMT-MM prepared ex situ.127
The esterification method was inspired by the work of Nishikubo et al., who reacted
poly(methacrylic acid) with alkyl halides in the presence of bases in aqueous mixtures.128
The reaction conditions were optimized to be suitable for the modification of HA with
propargyl derivatives (Table 2). HA was first dissolved in water; DMSO was added
dropwise under cooling on ice, followed by addition of other reagents.
Table 2 Excerpt of esterification conditions tested for the preparation of HA-propargyl
esters.III
 RXa Baseb [HA]:[RX]:[Base] [HA] /
g L-1
H2O/DMSO
(v/v)
T /
°C
t /
h
DS /
%
Mnc /
%
1 Br TEA 1.0 : 1.0 : 1.0 2.6 1 : 3 45 24 40 n.d.
2 Mes TEA 1.0 : 1.0 : 1.0 2.5 1 : 3 45 24 30 55
3 Mes TEA 1.0 : 3.0 : 3.0 2.5 1 : 3 60 20 26 30
4 Mes TEA 1.0 : 1.0 : 1.0 2.0 7 : 3 30 48 0 50
5 Br DBU 1.0 : 2.0 : 2.0 5.0 1 : 3 30 96 0 26
6 Br DBU 1.0 : 5.0 : 5.0 5.0 1 : 3 30 96 23 17
aSubstrate in base-catalyzed esterification: propargyl bromide or propargyl mesylate. bTEA  -
triethylamine, DBU - 1,8-diazabicyclo[5.4.0]undec-7-ene. cMolecular weight compared to starting
weight as determined by SEC.
3.2.2 Ring-opening polymerization of IGGII
Reactions were performed under stringent dry conditions in an argon atmosphere. (DL-1,2-
Isopropylidene glyceryl) glycidyl ether (IGG), prepared as reported,129 was polymerized in
presence of triisobutylaluminum (Al-iBu3) and an initiator (tetrabutylammonium azide,
NBu4N3, or tetraoctylammonium bromide, NOct4Br) in toluene (Table 3). Polymerizations
were initiated at -30 °C for 30 min, then continued at room temperature for 24 h, and
quenched with methanol. Conversions were typically 100 % as determined by 1H NMR.
Al-iBu3 was removed by precipitation in cold diethyl ether and filtration. The protected
polymers (PIGGs) were converted to their azide-derivatives by substitution of the bromide
head group with sodium azide, if necessary, and subsequently deprotected in presence of
trifluoroacetic acid to yield α-azido-poly(glyceryl glycerol) (N3-PGG). Gravimetric yields
were typically around 80-97 %.
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Table 3 Polymerization conditions and characteristics of polymers before (PIGG) and after
deprotection (PGG).
Polymer [IGG] /
M
Initiator [Al-iBu3]/[I] DPtheor. Mn,theor.a /
kg mol-1
Mn,SECb /
kg mol-1
PDISECb
PIGG-1 3.0 NBu4N3 4.0 40 7.5 7.4 1.29
PGG-1 - - - 40 5.9 3.5 1.49
PIGG-2 2.0 NBu4N3 5.0 40 7.5 5.1 1.27
PGG-2 - - - 40 5.9 2.3 1.53
PIGG-3 2.0 NBu4N3 5.0 20 3.8 6.6 1.39
PGG-3 - - - 20 3.0 3.1 1.62
PIGG-4 3.0 NOct4Br 4.0 67 12.6 13.9 1.60
PGG-4 - - - 67 9.9 9.2 1.45
PIGG-5 3.0 NOct4Br 4.0 67 12.6 11.1 1.13
PGG-5 - - - 67 9.9 5.8 1.21
PIGG-6 3.0 NOct4Br 4.0 51 9.6 9.1 1.36
PGG-6 - - - 51 7.6 3.5 1.25
aTheoretical molecular weight calculated from the molar ratio of monomer to initiator. Conversion
was 100 % in all polymerizations as determined by 1H NMR. bSEC of  PIGG in THF calibrated
with  polystyrene  standards;  SEC of  PGG in  0.1  M NaNO3 calibrated with poly(ethylene oxide)
standards.
3.2.3 Functionalization of PGG
3.2.3.1 Pyrene-ether of PGGIII
PGG-pyrene was prepared by Williamson ether synthesis (Scheme 6). PGG (1.0 eq.
hydroxyl groups) was activated with sodium hydride (1.2 eq.) in dry DMF and coupled
with 1-bromomethylpyrene (0.1 eq.). The product was purified by precipitation in cold
acetone and aqueous dialysis (Gravimetric yield: 63 %). The pyrene content was
determined by 1H NMR and UV spectroscopy.
Scheme 6 Synthesis of PGG-pyrene. Pyrene may be attached to any of the hydroxyl groups.
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3.2.3.2 Rhodamine B-labeling of PGG particlesII
N3-PGG  (3.5  kg  mol-1) was coupled to propargyl-functional poly(L-lactide) (PLLA, 5.9
kg mol-1) by copper-mediated azide-alkyne cycloaddition. The amphiphilic block
copolymers were assembled into particles of ~70 nm diameter by nanoprecipitation into
phosphate-buffered saline (PBS, pH 7.4). The particles exhibited a hydrophilic PGG-shell.
Particle dispersions were mixed with solutions of either rhodamine B-boronic acid or
plain rhodamine B, corresponding to 0.1 equivalent of PGG 1,2-diols. Subsequently, the
mixtures were dialyzed against PBS (molecular weight cut-off, MWCO 3.5 kg mol-1) until
no more dye was released into the dialysate as monitored by fluorescence spectroscopy.
The remaining dye concentration in the dispersions was determined by fluorescence
spectroscopy and compared to calibration curves of the individual dyes.
3.2.3.3 Synthesis of PGG-hydrazide
The procedure was inspired by the work of Liu et al.,130 but adapted to be suitable for
modification of PGG (Scheme 7). PGG (655 mg, 8.8 mmol hydroxyl groups, 1.0 eq.) was
dried in vacuum and dissolved in dry DMF (c = 10 mg mL-1) under argon. The solution
was cooled to 0 °C in an ice bath and sodium hydride (NaH, 55 % in mineral oil, 544 mg,
12.5 mmol, 1.4 eq.) was added under argon. The suspension was stirred in the thawing ice
bath overnight. Tetrabutylammonium iodide (NBu4I, 979 mg, 2.7 mmol, 0.3 eq.) was
added under argon at room temperature. Methyl bromoacetate (2.68 mL, 28.3 mmol, 3.2
eq.) was added dropwise via syringe. The mixture was placed in an oil bath at 40 °C and
stirred for 3 days. The crude mixture was subsequently added to 200 mL water under
stirring. The resulting yellow suspension was centrifuged for 10 min at 10 °C and 20 414 x
g. The pellet was dispersed in water and centrifuged again (3 times) and finally collected
with water and lyophilized to give a light beige powdery solid (PGG-acetate, gravimetric
yield: 205 mg, 31 %).
Hydrazine hydrate (80 %) was added to PGG-acetate (c = 20 mg mL-1) and the mixture
was stirred at 60 °C overnight. The resulting solution was diluted with water, dialyzed
(MWCO: 1000 g mol-1) against water for 3 days and lyophilized. Gravimetric yield: 188
mg, 92 % (DS = 33 % of repeating units by 1H NMR).
Scheme 7 Two-step synthesis of PGG-hydrazide: 1. etherification with methyl bromoacetate, 2.
hydrazinolysis. (unpublished)
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3.2.4 Copper-mediated azide-alkyne cycloadditions (CuAAC)III
The assessment of polysaccharide degradation under CuAAC conditions was performed
with HA-propargyl ester and sodium azide (NaN3) as a model compound.
Method A) To an aqueous solution of HA and NaN3 was added copper(II) sulfate
pentahydrate and sodium ascorbate under argon. The mixture was stirred at room
temperature and protected from light for 24 h.
Method B) A  solution  of  HA  and  NaN3 in water/DMSO (1:3 v/v) was degassed by
freeze-pump-thaw cycles. Copper(I) bromide and N,N,N’,N’’,N’’-pentamethyl-
diethylenetriamine (PMDETA) were added under argon and the mixture was stirred at
room temperature and protected from light for 24 h.
Both products were purified by aqueous dialysis in the presence of ethylenediamine-
tetraacetic acid (EDTA) to remove copper ions and lyophilized (Gravimetric yield > 92
%). The products were studied by SEC to determine their molecular weights.
Grafting of N3-PGG onto HA-propargyl ester was accomplished using method B. Graft
copolymers were purified by aqueous dialysis with large MWCO and, when indicated,
extracted with methanol.
3.3 Polymer-from-polymer release studiesIII
The  release  of  PGG-pyrene  grafts  from  the  HA-PGG  ester  graft  copolymer  was  studied
with two different setups.  HA-PGG (c = 1 mg mL-1)  was incubated in PBS (pH 7.40) at
37 °C.
3.3.1 SEC study
The incubation solution was distributed into Eppendorf vials (1 mL each), which were
placed in an oven at 37 °C. At predetermined intervals, samples were withdrawn and
frozen in liquid nitrogen. Samples were lyophilized and stored in a freezer until SEC
measurements. Immediately before the measurement, one sample at a time was thawed
and quickly mixed with SEC eluent containing 1 mg mL-1 uracil as an internal standard.
The sample was filtered and injected into the chromatograph. The resulting
chromatograms were referenced toward the uracil elution volume, baseline corrected,
smoothed, and integrated using OriginPro® 8.6 (OriginLab Corporation).
3.3.2 Dialysis study
Two microdialysis devices were used. Both devices were cylindrical in shape and had a
membrane attached to their base (Figure 6). The Slide-A-Lyzer® Mini (Thermo Scientific)
had  a  volume  of  100  µL  and  MWCO  of  20  kg  mol-1.  The  QuixSep® micro dialyzer
(Membrane Filtration Products) was equipped with a 25 kg mol-1 MWCO membrane
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(Spectra/Por,  Spectrum  Labs)  and  had  a  volume  of  1  mL.  Solutions  of  PGG-pyrene  or
HA-PGG-pyrene ester copolymer were loaded into the devices and dialyzed against PBS
at 37 °C under stirring. At preset times, the whole dialysate was replaced with fresh buffer
and the concentration of PGG-pyrene in the dialysate was determined by fluorescence
spectroscopy.
Figure 6 Dimensions of tested dialysis devices.
3.4 BiocompatibilityIII
The  cytotoxicity  of  PGG  and  HA-PGG  ester  copolymer  was  evaluated  in  four  different
cell lines by means of MTT assay. These included ARPE-19 cells (human retinal pigment
epithelial cell line, ATCC CRL-2302), HUVEC (human umbilical vein endothelial cells,
ATCC CRL-1730), SKOV-3 (human ovarian adenocarcinoma cells, ATCC HTB-77), and
CV-1 (monkey kidney fibroblast cells, ATCC CCL-70).
The  cells  were  seeded  in  96  well  plates  at  a  density  of  20  000  cells  per  well  and
incubated in growth medium overnight. After washing, the cells were incubated for 5 h
with polymers dissolved in growth medium. Branched poly(ethylene imine) (PEI, 25
kg mol-1) and polyvinyl alcohol (PVA, 30-70 kg mol-1) served as reference compounds.
After 5 h the polymer solutions were aspirated, the cells were washed and incubated in
growth medium for 24 h. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide)  solution  was  added  to  all  wells  and  incubated  for  4  h.  Formazan  crystals  were
dissolved with sodium dodecyl sulfate and hydrochloric acid overnight and quantified by
UV measurements at 570 nm. Cell viability was calculated as percent compared to
untreated cells.
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4 Results and Discussion
This section discusses the synthesis and chemical modification of the individual
components of the graft  copolymer,  as well  as the properties and release behavior of the
HA-PGG conjugate (Figure 7). First, functionalization of the HA backbone is presented,
followed by synthesis and post-polymerization modification of PGG side chains. The third
part addresses the grafting of PGG onto HA and finally the polymer-from-polymer release
is examined including studies of the biocompatibility of the materials.
HA-PGG graft
copolymers
Modification
of HA
Amidation
Esterification
Synthesis
of PGG
ROP
Functionalization
of PGG
Pyrene-ether
Boronic esters
PGG-hydrazide
Grafting of
PGG to HA
Click reaction
Purification
Release studies
Stability of
derivatives
Release kinetics
Biocompatibility
Figure 7 Schematic representation of the topics covered in the Results and Discussion section.
4.1 Modification of hyaluronic acid
HA was functionalized with reactive linkers for subsequent grafting of polymer side
chains. The glucuronic acid moieties were converted into amides or esters. Ester bonds
can be rapidly hydrolyzed in the neutral aqueous environment of the vitreous, while amide
bonds are stable.28 Reactive amide linkers can be used to attach probes to the HA
backbone to follow its fate in the vitreous independent of the side chains. Furthermore
amide-linked graft copolymers may be degraded by HA-digesting enzymes, resulting in
polymer grafts carrying HA fragments (Scheme 8). The chemical modification of HA was
investigated with respect to achievable degree of substitution (DS) and minimal
polysaccharide degradation.
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Scheme 8 Cleavage of side chains from HA graft copolymers with ester or amide linkages. a)
Hydrolysis of ester bonds under neutral aqueous conditions. b) Release of grafts
carrying HA fragments upon hyaluronidase-mediated degradation of the backbone.
4.1.1 Triazine-mediated amidationI
HA was reacted with several clickable amines using 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-
4-methylmorpholinium chloride (DMT-MM) to activate the glucuronic acid groups. DS of
amidated HAs was found to decrease with increasing basicity of the amine reagent (Table
4). The difference in DS was explained in view of the reaction mechanism (Scheme 9).
First, the HA-carboxylate attacks DMT-MM to form the “superactive ester” (AE). The
ester is then attacked by the amine, forming a tetrahedral intermediate (TI), and finally
collapses to expel a leaving group (LG). In case of the “superactive” triazine ester,
breakdown of TI is energetically favored by the tautomeric rearrangement of LG.131
Therefore the amine attack becomes the rate-limiting process, which is only possible if the
amine is not protonated. Conducting the reaction under neutral aqueous conditions
resulted in amines with increasing basicity being increasingly protonated and hence
inactive.
Table 4 Degree of substitution of HA amide derivatives prepared from different amines.I
Derivative Amine reagent pKa of amine DSa / %
HA-propargyl Propargyl amine hydrochloride 8.2 54.5 ± 4.4
HA-maleimide N-(2-Aminoethyl)-maleimide trifluoroacetate 8.4 39.5 ± 2.6
HA-methacrylate 2-Aminoethylmethacrylate hydrochloride 8.8 41.3 ± 6.1
HA-allyl Allylamine 9.5 28.2 ± 2.2
HA-thiol Cysteamine hydrochloride 10.8 3.7 ± 0.7
aFrom 1H NMR in D2O/DMSO-d6 (1:1 v/v), average of three integrations ± standard deviation.
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Scheme 9 Mechanism of triazine-mediated amidation of HA with propargyl amine.
At the time of this finding, the factors influencing the outcome of triazine-mediated
amidations had not been established yet. D’Este et al. published a study concurrent to this
work, hypothesizing that the reaction rate did not depend on the concentration of the HA-
triazine ester.92 Using 1H NMR spectroscopy, we investigated the kinetics of HA
activation and the stability of the coupling agent in aqueous solution. The latter was
important as HA coupling reactions are often pursued for several days, but the stability of
DMT-MM  was  only  documented  for  3  h.127 The  coupling  reagent  was  found  to  slowly
hydrolyze in D2O (t1/2 ~9.2 d). The hydrolysis product, 2-hydroxy-4,6-dimethoxy-1,3,5-
triazine (DMT-OH), rearranged to 4,6-dimethoxy-1,3,5-triazin-2-one and subsequently
isomerized to a stable isocyanuric acid derivative by O→N migration of one methyl group
(Scheme 10). Isomerization of DMT-OH was rapid (Figure 8a). In the presence of HA,
DMT-MM was consumed faster and the HA-triazine ester, although indistinguishable
from DMT-OH by 1H NMR, was formed quantitatively (1.5 eq. of coupling agent was
used compared to HA carboxyls) and remained stable for about 10 days in the mixture
(Figure 8b).
Scheme 10 Hydrolysis of DMT-MM to DMT-OH and N-morpholinium chloride, followed by
rearrangement and isomerization of DMT-OH into the isocyanuric acid derivative.
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Figure 8 1H NMR kinetics of DMT-MM consumption and appearance  of DMT-OH or active
HA-ester as wel as formation of isocyanuric acid derivative over time. The lines in
graphs a)-c) are to guide the eye. a) DMT-MM hydrolysis in D2O, b) DMT-MM +HA
in D2O, c) DMT-MM + HA + amine in D2O. DS is the degree of substitution of
amidated HA. d) First-order kinetic plot of DMT-MM consumption in presence and
absence of HA and amine.I
In the presence of propargyl amine, the “superactive ester” was immediately converted
to the amide (Figure 8c). The rate of coupling agent consumption was similar in the amine
mixture and in presence of HA alone (Figure 8d). Therefore, the amine had no
accelerating efect on the formation of the HA-triazine ester. After about 10 h, the
amidation rate slowed down, which was atributed to a change in acid-base equilibrium.
The amine stoichiometry appeared to be the limiting factor for the DS,i.e. the use of 1.1
or 1.5 eq. of propargyl amine compared to HA carboxylate resulted in DS of 40 and 53 %,
respectively. At higher initial reagent concentration relatively more deprotonated amines
existed in the mixture, which was in accordance with previous findings.
HA-propargyl amide was obtained with the highest coupling eficiency at near
stoichiometric reagent ratios and displayed excelent water solubility. The alkynyl
moieties were stable upon storage and able to react orthogonaly with azides in CuAAC.
Hence the focus of further studies was placed on HA-propargyl derivatives for eficient
grafting of side chains. The triazine-mediated amidation preserved on average 80 % of the
molecular weight of the polysaccharide (Table 5).
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Table 5 Molecular weights and PDI of HA-amide derivatives.a (unpublished)
Derivative Mn / kg mol-1 PDI  Mn / %
HA 422 1.15 100
HA-propargyl 331 1.26 78
HA-allyl 415 1.17 98
HA-thiol 284 1.36 67
aSEC in 0.1 M NaNO3 calibrated with pullulan standards.
4.1.2 EsterificationIII
Esterification of HA was accomplished in a mixed solvent system (water/DMSO 1:3 v/v)
without prior acidification of HA or counter ion exchange. The reaction was base
catalyzed, using propargyl derivatives with a good leaving group, and stoichiometric
reagent ratios. Propargyl bromide gave slightly higher DS compared with propargyl
mesylate (Experimental, Table 2, entries 1&2), while no esterification was observed in
mixtures with higher water content (Table 2, entry 4). The type of base had a strong effect
on reaction outcome. Triethylamine (TEA) was more efficient in mediating the
esterification than 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), supposedly due to its non-
nucleophilic nature (Table 2, entries 1&5). DS were comparably high, varying between 17
and 40  %,  and  reactions  at  45  °C for  24  h  with  1  equivalent  of  TEA in  respect  to  HA-
carboxylate groups resulted in the least polysaccharide degradation with preservation of
~50 % of the molecular weight. Overall, the degradation was more pronounced during the
esterification than amidation (Figure 9).
14 16 18 20 22 24 26 28
Elution volume / mL
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HA-propargyl amide
HA-propargyl ester
Figure 9 SEC traces of HA and HA-propargyl amide and ester.III
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The 1H NMR spectra of HA and HA-propargyl amide and ester are shown in Figure
10. As expected the propargyl ester signals were shifted downfield compared to the
propargyl amide peaks due to deshielding induced by the electronegative oxygen.
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Figure 10 1H NMR spectra of (from bottom) HA, HA-propargyl amide and HA-propargyl
ester in D2O with chemical structures and assignment of characteristic peaks.I, III
4.2 Synthesis of poly(glyceryl glycerol)
4.2.1 Ring-opening polymerization of IGGII
α-Azido-poly(glyceryl glycerol) (N3-PGG) was synthesized by monomer-activated ring-
opening polymerization (ROP) of (DL-1,2-isopropylidene glyceryl) glycidyl ether (IGG) in
presence of triisobutylaluminum (Al-iBu3, Scheme 11). The polymerization mechanism
relies on formation of a stoichiometric complex between the tetraalkylammonium initiator
and Al-iBu3 and simultaneous activation of the epoxide monomer by coordination to Al-
iBu3. Therefore the aluminum species has to be employed in excess compared to the
initiator with the ratio depending on the structure of the monomer.  Monomers consisting
of multiple oxygen atoms, such as IGG, generate growing polymer chains with a tendency
to complex aluminum, which is hence not available for activation.132 For ROP of IGG (at
a certain monomer concentration and targeting a certain DP) the optimal ratio of
[Al-iBu3]:[initiator] was 4 (Experimental, Table 3). At lower ratios the reaction did not
proceed to completion, while at higher ratios broadened molecular weight distributions
were observed, due to aluminum-induced transfer reactions.
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Scheme 11 Mechanism of monomer-activated ROP of IGG and subsequent quenching and
deprotection.
Using this technique, polymers with higher degrees of polymerization (DP > 40) could
be  obtained  than  with  previously  reported  methods  (i.e. alkoxide initiated ROP).129 Two
different initiators were employed to obtain α-functional polymers. Tetrabutylammonium
azide (NBu4N3) gave α-azido-PIGG directly, while use of tetraoctylammonium bromide
(NOct4Br) resulted in α-bromo-functional polymers. NOct4Br led to narrower molecular
weight distribution of the products in accordance with the reported polymerization kinetics
enhancing effect of larger counter ions (Figure 11). The bromide head group was easily
substituted with sodium azide to yield the desired clickable polymers for grafting to HA-
propargyl derivatives (Figure 12). The isopropylidene protecting groups were removed by
acidic treatment to liberate the pendant 1,2-diol moieties.
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PGG-3
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NBu4N3-initiated ROP NOct4Br-initiated ROP
Figure 11 SEC traces of PGGs polymerized with NBu4N3 (left) or NOct4Br (right).II
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Figure 12 FT-IR spectra of (from top) Br-PIGG, N3-PIGG after substitution of the head group
and N3-PGG after deprotection. The azide peak is enlarged in the inset.II
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Figure 13 1H NMR spectra of (from top) IGG monomer, crude PIGG after
polymerization, PIGG after precipitation of Al-iBu3 and deprotected PGG. Frames
highlight the signals that disappear after each step.II
Figure 13 shows the 1H NMR spectra of the monomer (IGG) and the crude polymer at
100 % conversion. Removal of the aluminum species by precipitation in diethyl ether as
well as successful deprotection were confirmed by NMR. The molecular weights of the
protected polymers (PIGGs) were close to the theoretical values, according to SEC against
polystyrene standards and assuming that every initiator molecule starts one polymer chain
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(Experimental, Table 3). The molecular weights of deprotected PGGs are underestimated,
due to the difference in solution properties of linear poly(ethylene oxide) standards and the
compact, side chain substituted polyglycerols.112 The prepared PGG chains (~10 kg mol-1)
have molecular weights well below the renal threshold reported for PEG (~30 kg mol-1)133
and possess around 130 hydroxyl groups for conjugation with drugs, probes and targeting
ligands.
4.2.2 Functionalization of PGG
In contrast to PEG, PGG is only soluble in polar solvents, such as water, DMSO, DMF, N-
methyl-2-pyrrolidone, methanol, ethanol, and pyridine. Therefore the conjugation of PGG
with drugs, probes and targeting molecules is more challenging. Different strategies were
explored to functionalize PGG with model compounds.
4.2.2.1 Pyrene-ether of PGGIII
1-Bromomethylpyrene was conjugated to PGG by Williamson ether synthesis to act as
both a fluorescent tag for release studies and as a hydrophobic model compound. PGG-
pyrene  was  found  to  contain  0.12  mol%  of  the  tag  per  PGG  repeating  unit  or  7.9  µg
pyrene per 1 g polymer as determined by UV and 1H NMR. The modification had no
effect on the molecular weight distribution of the polymer (Figure 14a). PGG-conjugated
pyrene showed increased water solubility compared with uncoupled pyrene, but
maintained its characteristic UV and fluorescence properties (Figure 14b). No excimer
fluorescence was observed in the studied concentration range (up to 10 mg mL-1 polymer
concentration), indicating that the pyrene moieties were randomly distributed along the
polymer chain.
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Figure 14 a) SEC traces of PGG-pyrene and its precursor polymer. b) UV and fluorescence
spectra of PGG-pyrene in PBS.III
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4.2.2.2 Boronic ester of PGGII
Compared  with  polyglycerol,  PGG has  the  ability  to  form dynamic  covalent  bonds  with
boronic acid derivatives. The pendent 1,2-diol groups in PGG spontaneously reacted with
boronic acids to boronic esters under liberation of water (Scheme 12). NMR spectra of an
equimolar mixture of PGG diols and phenylboronic acid (PBA) in deuterated methanol
(MeOD) showed the appearance of new signals attributed to boronate-bound PGG
repeating units (4.0 - 4.7 ppm), as well as shifts in the aromatic peaks of PBA (Figure
15a). The new signals had similar translational diffusion coefficients as the PGG backbone
in diffusion-ordered (DOSY) NMR spectra, thus proving their attachment to the polymer
(Figure 15b). Integration of the signals gave the equilibrium degree of esterification of 33
% under the given conditions.
Scheme 12 Boronic ester formation between PGG and a boronic acid derivative.
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Figure 15 a) 1H NMR spectra of (from top) PBA, PGG and an equimolar mixture of PGG/PBA
in MeOD. b) Signal intensity versus gradient strength of peaks in the PGG/PBA
mixture marked in a) determined by DOSY NMR (diffusion delay 100 ms, 16 spectra
with linearly incremented gradient strength). Diffusion coefficients were calculated
from the slope of the curves.II
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PGG boronic ester formation was further demonstrated under physiologically relevant
conditions (PBS, pH 7.4). Although literature reports have described glycerol boronic
esters as weak and hydrolytically unstable,134 the  interaction  of  PGG  with  rhodamine  B
boronic acid was found to be strong enough for efficient fluorescence labeling of the
polymer (Table 6). PGG chains were anchored at the surface of model polymeric
nanoparticles to facilitate their separation from uncoupled dye molecules. Therefore, PGG
was conjugated to hydrophobic poly(L-lactide)  (PLLA)  via  CuAAC.  The  amphiphilic
block copolymers were assembled into particles of 70 nm diameter by nanoprecipitation
into PBS. The formed particles displayed a PGG corona that could be functionalized post-
assembly by simple addition of boronic acids. PGG particles were mixed with 10 mol% of
a dye compared to diol concentration and then extensively dialyzed. With rhodamine B
boronic  acid,  86  % of  the  dye  was  retained  after  dialysis,  while  plain  rhodamine  B was
completely removed. The high labeling efficiency (LE) was ascribed to the favorable
interactions in polyols, i.e. steric bulk hindering the attack of water and thus hydrolysis, as
well as favorable entropy due to the large number of possible boronic esters and
isomers.135
Table 6 Labeling efficiency (LE) of PGG particles with rhodamine B boronic acid or
rhodamine B after extensive dialysis.II
Sample c0a / 10-5 M cdyeb / 10-5 M LE / %
Rhodamine B boronic acid 28.7 24.6 85.5
Rhodamine B 28.7 0.06 0.2
aTheoretical dye concentration in a 1 mg mL-1 dispersion of PGG particles. bExperimental dye
content in a 1 mg mL-1 dispersion of PGG particles after extensive dialysis determined by
fluorescence spectroscopy.
Boronic ester formation between PGG and functional boronic acids is an attractive
strategy for fast and simultaneous conjugation of multiple probes and targeting moieties
under mild conditions. The strategy is also applicable to specific labeling of PGG in HA-
PGG graft copolymers, as HA does not feature the reactive cis-diol motif. The stability of
PGG boronic esters in presence of diol-containing biomolecules, such as carbohydrates or
glycoproteins, needs further investigation to evaluate the usefulness of the approach for
targeted drug delivery.
4.2.2.3 PGG-hydrazide
Hydroxyl groups exhibit a relatively low nucleophilicity compared to other functional
groups (e.g. amines, carboxylates, and thiols) and their modification is often complicated
in the presence of water. To achieve efficient coupling of PGG with bioactive molecules,
its pendant hydroxyl groups were converted into more reactive moieties. PGG was first
reacted with methyl bromoacetate in another Williamson ether synthesis and subsequently
aminolyzed with hydrazine to yield hydrazide groups. Hydrazides can be conjugated with
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aldehyde/ketone groups in drug molecules (e.g. dexamethasone) leading to acid-labile
hydrazones, or they can react with activated carboxyls or isothiocyanates to form amide or
thiourea derivatives (Scheme 13). Hence, PGG-hydrazide enables the coupling of many
commercially available probes and targeting ligands.
Scheme 13 Possible pathways for functionalization of PGG-hydrazide with drugs, probes and
targeting moieties: (from top) hydrazone formation with aldehydes/ketones,
amidation with active ester derivatives, thiourea formation with isothiocyanates.
600110016002100260031003600
Wavenumber / cm-1
PGG
PGG-acetate
PGG-hydrazide
O-H
stretch
ester C=O
stretch
amide C=O
stretch
N-H
bending
ester C-O stretch
Figure 16 FT-IR spectra of (from top) PGG, PGG-acetate and PGG-hydrazide with assignment
of characteristic signals. (unpublished)
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DS obtained ranged between 20 and 42 % of hydrazide per PGG repeating unit, which
corresponds to about 15-28 hydrazide groups per polymer chain (DP = 67). Full
conversion of the hydroxyl groups was impeded by the partial insolubility of PGG-
alkoxides in DMF during the ether synthesis. The acetylated PGG derivative was insoluble
in common solvents and could only be analyzed by FT-IR spectroscopy. However, Figure
16 shows a reduction in hydroxyl peak intensity in PGG-acetate compared to PGG, as well
as a strong ester carbonyl stretching band at 1744 cm-1 and C-O stretching bands at 1223
and 1280 cm-1. After hydrazinolysis, the carbonyl stretching peak in PGG-hydrazide was
shifted completely to the amide frequency (1658 cm-1), and N-H bending (1600 cm-1) and
stretching (3319 cm-1) bands appeared. PGG-hydrazide was soluble in DMSO and water.
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Figure 17 HSQC NMR of PGG-hydrazide in DMSO-d6. Inset shows the structure and peak
assignment. (unpublished)
The structure of PGG-hydrazide was confirmed by NMR spectroscopy. Figure 17
shows the heteronuclear single quantum coherence (HSQC) NMR spectrum of PGG-
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hydrazide in DMSO-d6. The peaks were assigned based on homo- and heteronuclear
correlation spectra (data not shown).
4.3 Grafting of PGG onto HAIII
4.3.1 Click reaction conditions
Prior  to  grafting  of  N3-PGG onto HA-propargyl derivatives, different CuAAC reaction
conditions were tested for their potential to degrade HA. It is known that in situ reduction
of copper(II) sulfate by sodium ascorbate to produce the catalytically active Cu+ species
creates hydroxyl radicals, which degrade HA.136 The  same  was  observed  in  this  study.
Figure 18 shows the SEC traces of HA-propargyl ester derivatives treated under click
reaction conditions with sodium azide as a model reaction partner to avoid changing the
solution properties of the polysaccharide. The derivative treated with Cu(II) and ascorbate
retained only about 25 % of its original molecular weight, while a reaction using copper(I)
bromide and a ligand in water/DMSO (1:3 v/v) preserved 71 % of the molecular weight.
Therefore the grafting was conducted using the latter conditions.
18 20 22 24 26 28 30
Elution volume / mL
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HA-ester clicked with Cu(I)
HA-ester clicked with Cu(II)
Figure 18 SEC traces of HA-propargyl ester and HA derivatives after model click reactions
catalyzed by copper(I) bromide or copper(II) sulfate / ascorbic acid.III
PGG-pyrene was grafted to HA-propargyl ester to obtain a fluorescently labeled graft
copolymer with hydrolysable bonds for release studies (Scheme 14). Upon grafting, the 1H
NMR peaks of the HA-propargyl moieties disappeared and the characteristic signals of the
triazole ring and the adjacent methylene group appeared (Figure 19), proving the success
of the reaction.
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Scheme 14 Click grafting of PGG-pyrene onto HA-propargyl ester.
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Figure 19 1H NMR spectra of HA-propargyl ester and HA-PGG graft copolymer after click
reaction. The spectral areas where peak shifts occur are enlarged. Peaks are
assigned according to Scheme 14.III
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4.3.2 Purification of HA-PGG graft copolymers
SEC measurements of HA-PGG showed an increase in molecular weight of the graft
copolymer compared to HA-propargyl ester (Figure 20). The shift to lower elution
volumes was rather small and attributed to the flexible and compact nature of PGG. The
measurements also revealed an excess of uncoupled PGG chains that were not removed by
dialysis (using a 25 kg mol-1 MWCO  to  remove  3.1  kg  mol-1 uncoupled  PGG).  The
majority of uncoupled PGG could be removed by extraction of the lyophilized copolymer
with methanol, which is a non-solvent for HA but dissolves PGG. In order to ensure
accurate release results, the content of uncoupled PGG in the studied material was always
determined at the start of the experiment (t = 0).
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Figure 20 SEC traces of HA-propargyl ester and HA-PGG click product after purification by
dialysis and extraction.III
4.4 Release studiesIII
The properties of HA-propargyl derivatives and HA-PGG ester graft copolymers were
studied under simulated physiological conditions. The materials were incubated in either
PBS or 10 % (v/v) porcine vitreous liquid in PBS at pH 7.4 and 37 °C. Changes in the
molecular weight and chemical structure of the materials were investigated and their
biocompatibility was tested in cell cultures.
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4.4.1 Stability of HA derivatives during incubation
HA and HA-propargyl derivatives were incubated for 36 days to estimate the extent of
polysaccharide backbone degradation via non-enzymatic and enzymatic hydrolysis.
Neither native HA nor HA derivatives showed pronounced degradation during the
experiment. The SEC traces of HA-propargyl ester were slightly shifted to higher elution
volumes (Figure 21a), supposedly due to the loss of the propargyl linker upon ester
hydrolysis. The magnitude of the shift was the same in PBS and vitreous-containing
buffer. The molecular weight distribution of HA-propargyl amide remained unchanged
after incubation in PBS, but the peak maximum was shifted slightly after incubation in
vitreous (Figure 21b). A similar behavior was observed for native HA. The overall
degradation of the polysaccharides was found to be negligible and will not affect the
release of side chains from the graft copolymer.
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a) HA-propargyl ester b) HA-propargyl amide
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36 days in PBS
36 days in 10 %
(v/v) vitreous
Figure 21 SEC traces of HA-propargyl ester (a) and amide (b) before and after incubation in
PBS or 10 % (v/v) vitreous liquid in PBS at 37 °C for 36 days.III
The structural changes of the HA-derivatives upon incubation were studied by NMR
spectroscopy. The propargyl ester was completely cleaved after 36 days of incubation in
both media, while the propargyl amide was still intact (Figure 22). The area of the
propargyl amide signal decreased from about 40 % DS to roughly 30 % DS, indicating
slow hydrolysis of the linkage.
4.4.2 Release kinetics
The kinetics of HA-propargyl ester hydrolysis were studied in situ by NMR spectroscopy.
The derivative was incubated in PBS containing 5 % (v/v) D2O at  37  °C to  emulate  the
conditions used in the release experiments. Hence, 1H NMR spectra had to be acquired
using a water suppression pulse sequence. The signals of propargyl ester (~3.0 ppm) and
its hydrolysis product, propargyl alcohol (~2.8 ppm), were followed with time. Half-life of
the  HA-propargyl  ester  was  found  to  be  about  3.9  h  (Table  8).  The  value  was  in
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accordance with the report of a more hydrophobic HA-corticosteroid ester, which
exhibited t1/2 ~ 6.5 h.137
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Figure 22 1H NMR spectra of HA-propargyl ester (left) and amide (right) before (top) and after
incubation in PBS (middle) or 10 % (v/v) vitreous liquid in PBS (bottom). Propargyl
peaks are marked with arrows. *N-methylmorpholinium impurity from amidation.
**Signals originating from the vitreous.III
The polymer-from-polymer release of PGG grafts from the ester-linked HA-PGG graft
copolymer was investigated using two types of setups. Pyrene-modified PGG was used to
enable detection of released chains. All experiments were conducted in PBS at 37 °C.
First, in a dialysis setup released PGG-pyrene was separated from the incubation mixture
by diffusion across the membrane. The concentration of PGG-pyrene in the dialysate was
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determined by fluorescence. Second, the composition of the incubation mixture was
measured directly by SEC. Samples were withdrawn at specific time points and subjected
to SEC measurements. The amount of released PGG-pyrene was determined by
integration of the PGG elution peak.
The permeability of PGG-pyrene (9.2 kg mol-1) across the membranes of two different
dialysis devices (MWCO ~20 kg mol-1;  Experimental,  Figure  6)  was  studied.  The
combination of miniaturized dialysis setups and fluorescence detection can significantly
reduce the amount of polymer material required for release experiments. Furthermore, the
high ratio of membrane surface area to sample volume (SA:V) in these devices can
increase the rate of analyte permeation. PGG-pyrene was completely released from the
Slide-A-Lyzer® device after 48 h, while the majority of the polymer was still trapped
within the QuixSep® device (Figure 23a). The difference in dialysis efficiency was likely
due to the 5-times larger SA:V ratio of the Slide-A-Lyzer® in this specific experiment
(Table 7).
0
20
40
60
80
100
0 1 2 3 4 5 6 7 8
R
es
id
ua
lE
st
er
/%
Time / d
HA-PGG-pyrene (SEC)
HA-PGG-pyrene (Dialysis)
HA-propargyl ester (NMR)
0
20
40
60
80
100
0 8 16 24 32 40 48
Re
sid
ua
lP
G
G
-p
yr
en
e
/%
Time / h
QuixSep®
Slide-A-Lyzer®
a) b)
Figure 23 Release kinetics determined in PBS at 37 °C: a) Release of PGG-pyrene from
QuixSep® or Slide-A-Lyzer®. b) Release of PGG-pyrene from the HA graft
copolymer studied by SEC and dialysis (Slide-A-Lyzer®), and cleavage of ester bonds
in HA-propargyl ester studied by 1H NMR. Data is reported as mean (n=2-3) ±
standard deviation and fitted with the integrated ester hydrolysis rate law shown in
b).III
Table 7 Characteristics of dialysis devices.III
Dialysis
device
MWCO /
kg mol-1
Sample /
µL
Dialysate /
mL
Volume
ratio
Membrane
surface area / cm2
SA:Va /
cm2 mL-1
QuixSep® 25 800.0 30 37.5 1.77 2.21
Slide-A-
Lyzer®
20 26.7 1 37.5 0.28 10.59
aSurface area-to-volume ratio.
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The release of PGG-pyrene from the HA graft copolymer was complete after 1 week in
both release experiments (dialysis and SEC, Figure 23b). In case of the SEC study, the rate
of ester bond hydrolysis was determined by fitting of the data with the integrated ester
hydrolysis rate law (see inset of Figure 23b). The data obtained from the dialysis study
was fitted with equation (4), taking into account the different setup. The appearance of
free PGG-pyrene in the dialysate is governed by two processes, i.e. hydrolysis of the HA-
PGG graft copolymer within the dialysis device (equation (1)) and diffusion of free PGG
across the membrane (equation (3) and Figure 24). This can be considered as a
consecutive reaction, and thus the individual rate constants of hydrolysis and diffusion
(khydr. and kdiff.) could be separated. The obtained khydr. was in excellent agreement with the
rate constant determined in the SEC experiment (Table 8).
(1)
(2)
(3)
(4)
Figure 24 Model describing the consecutive release of PGG from the graft copolymer and
subsequent diffusion from the dialysis device.III
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Table 8 Hydrolysis and diffusion rate constants, as well as half-lives of HA derivatives in PBS
at 37 °C.III
khydr / 10-2 h-1 kdiff / 10-2 h-1 t1/2a / h adj. R2 b
HA-PGG-pyrene (SEC) 2.95 ± 0.27 - 23.51 ± 2.19 0.986
HA-PGG-pyrene (Dialysis) 2.97 ± 0.38 10.50 ± 3.31 23.34 ± 3.04 0.997
HA-propargyl ester (NMR) 17.63 ± 1.00 - 3.93 ± 0.22 0.970
aThe half-life was calculated according to t1/2 = ln(2) / khydr. bCoefficient of determination adjusted
by the degrees of freedom of the fit model.
The hydrolysis of the HA-PGG graft copolymer (t1/2 ~23.4 h) was considerably slower
than that of the HA-propargyl ester derivative (t1/2 ~3.9 h). The slow release of polymeric
side chains, as compared to small molecular linkers, was attributed to steric crowding in
the graft copolymer, shielding the ester bonds from attack by water molecules. A graft
copolymer with cleavable drug-carrying polymer side chains thus has the potential to
achieve longer lasting release than a mere prodrug with drug molecules attached to the
backbone.
4.4.3 Biocompatibility
Biocompatibility studies were performed with the HA-PGG graft copolymer and PGG
grafts. The viability of different cell lines after incubation with polymers was investigated
by MTT cytotoxicity assay. Human retinal pigment epithelial cells (ARPE-19) and human
umbilical vein endothelial cells (HUVEC) were selected for their relevance in ocular drug
development. Monkey kidney fibroblasts (CV-1) and human ovarian adenocarcinoma cells
(SKOV-3) were studied to assess the general cytotoxicity of the materials toward healthy
and diseased cells. The cells were incubated with different concentrations of polymers for
5 h and in growth medium for 20 h. The metabolic activity of the cells was measured
spectrophotometrically after addition of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT), which is reduced to purple formazan in the mitochondria of
living cells.
The  cell  viability  after  incubation  with  HA-PGG  or  PGG  was  compared  with  the
response induced by polyvinyl alcohol (PVA), which is non-toxic and FDA-approved for
ocular use, and branched poly(ethylene imine) (PEI), which is known to be cytotoxic. HA-
PGG and PGG exhibited  similar  levels  of  cell  viability  to  PVA for  concentrations  up  to
0.1 mg mL-1 (Figure 25), which is the envisioned concentration in the vitreous after
injection. At higher concentrations both polymers decreased the cell viability compared to
PVA, although HA-containing polymers were better tolerated. The effect may originate
from residual impurities from the synthesis, especially the copper-mediated click grafting.
Metal impurities may be further reduced by filtration over an ion exchange resin. The
polymers were much less toxic than PEI and are thus considered promising biomaterials.
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Figure 25 Cell viability versus polymer concentration determined by MTT assay of a) human
retinal pigment epithelium (ARPE-19), b) human umbilical vein endothelial cells
(HUVEC), c) monkey kidney fibroblasts (CV-1), and d) human ovarian
adenocarcinoma cells (SKOV-3). Cells were incubated with HA-PGG graft
copolymer, PGG, FDA-approved PVA or cytotoxic PEI. Data is presented as mean of
three experiments (except HUVEC) ± standard deviation.III
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5 Conclusions
The synthesis of water-soluble hyaluronic acid (HA) graft copolymers was studied in
detail and the suitability of the copolymers as vehicles for intravitreal drug delivery was
examined. High molecular weight HA was modified with clickable propargyl-linkers for
grafting onto of multifunctional side chains. The linkers were introduced via amidation or
esterification to yield stable or hydrolysable bonds. The reaction conditions were
optimized to reduce HA degradation and to yield comparatively high degrees of
substitution at stoichiometric reagent ratios. Amidation was found to induce less
degradation of HA than esterification.
Complementary click functional side chains were prepared by monomer-activated
ring-opening polymerization of protected glycidyl ethers. The resulting polymers were α-
azido-polyethers with pendant 1,2-diol moieties in every repeating unit, i.e. poly(glyceryl
glycerol) (PGG). Using a Lewis acid catalyst, degrees of polymerization of PGG >40 were
achieved for the first time, resulting in polymers with >100 pendant functional groups and
molecular  weights  below  the  renal  threshold.  The  diols  were  amenable  to  labeling  with
boronic acid derivatives with high efficiency in neutral aqueous solution. Part of the PGG
hydroxyls were further converted into reactive hydrazide groups for subsequent
attachment  of  drugs  and  into  pyrene  ethers  for  detection  in  release  studies.  Grafting  of
PGG onto HA-propargyl ester was achieved by copper-mediated azide-alkyne cyclo-
addition, producing water-soluble graft copolymers with cleavable arms.
The materials were incubated under simulated vitreal conditions to determine their
stability and release behavior. HA and its derivatives showed no sign of polysaccharide
degradation within a month. HA-propargyl esters were completely cleaved after 1 week,
while amide bonds remained mostly intact. Hydrolysis of propargyl esters was followed
by NMR, whereas polymer-from-polymer release of PGG grafts from the HA-PGG ester
graft copolymer was studied by SEC and dialysis. The rate of cleavage of PGG chains was
significantly lower than the hydrolysis of the small molecular propargyl linker, and was
attributed to steric crowding at the ester carbonyl. Biocompatibility tests were performed
in cell cultures. PGG and HA-PGG graft copolymers exhibited similar levels of cell
viability as polyvinyl alcohol, a FDA-approved polymer for ocular use.
Thus, HA-based graft copolymers with cleavable arms are promising materials for
intravitreal drug delivery applications. They have the potential to achieve long retention
times in the vitreous due to their high molecular weight. The slow cleavage of polymer
grafts allows for longer-lasting release than a direct release of drugs from a polymer.
Using the presented strategies, the grafts can be further conjugated with drugs, probes and
targeting ligands, and tested in ophthalmic applications.
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